These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 7952656)

  • 21. Crystal structure of chemically synthesized HIV-1 protease and a ketomethylene isostere inhibitor based on the p2/NC cleavage site.
    Torbeev VY; Mandal K; Terechko VA; Kent SB
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4554-7. PubMed ID: 18657969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 protease folding and the design of drugs which do not create resistance.
    Broglia R; Levy Y; Tiana G
    Curr Opin Struct Biol; 2008 Feb; 18(1):60-6. PubMed ID: 18160276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On the role of the R configuration of the reaction-intermediate isostere in HIV-1 protease-inhibitor binding: X-ray structure at 2.0 A resolution.
    Dusková J; Dohnálek J; Skálová T; Petroková H; Vondrácková E; Hradílek M; Konvalinka J; Soucek M; Brynda J; Fábry M; Sedlácek J; Hasek J
    Acta Crystallogr D Biol Crystallogr; 2006 May; 62(Pt 5):489-97. PubMed ID: 16627941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The crystal structure of protease Sapp1p from Candida parapsilosis in complex with the HIV protease inhibitor ritonavir.
    Dostál J; Brynda J; Hrušková-Heidingsfeldová O; Pachl P; Pichová I; Rezáčová P
    J Enzyme Inhib Med Chem; 2012 Feb; 27(1):160-5. PubMed ID: 22146051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease.
    Mazumder A; Wang S; Neamati N; Nicklaus M; Sunder S; Chen J; Milne GW; Rice WG; Burke TR; Pommier Y
    J Med Chem; 1996 Jun; 39(13):2472-81. PubMed ID: 8691444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New active HIV-1 protease inhibitors derived from 3-hexanol: conformation study of the free inhibitors in crystalline state and in complex with the enzyme.
    Ziółkowska NE; Bujacz A; Randad RS; Erickson JW; Skálová T; Hašek J; Bujacz G
    Chem Biol Drug Des; 2012 May; 79(5):798-809. PubMed ID: 22296826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimization and computational evaluation of a series of potential active site inhibitors of the V82F/I84V drug-resistant mutant of HIV-1 protease: an application of the relaxed complex method of structure-based drug design.
    Perryman AL; Lin JH; Andrew McCammon J
    Chem Biol Drug Des; 2006 May; 67(5):336-45. PubMed ID: 16784458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
    Jadhav PK; Woerner FJ; Lam PY; Hodge CN; Eyermann CJ; Man HW; Daneker WF; Bacheler LT; Rayner MM; Meek JL; Erickson-Viitanen S; Jackson DA; Calabrese JC; Schadt M; Chang CH
    J Med Chem; 1998 Apr; 41(9):1446-55. PubMed ID: 9554878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of HIV protease inhibitors: a survey.
    Ren S; Lien EJ
    Prog Drug Res; 1998; 51():1-31. PubMed ID: 9949858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid discovery and structure-activity profiling of novel inhibitors of human immunodeficiency virus type 1 protease enabled by the copper(I)-catalyzed synthesis of 1,2,3-triazoles and their further functionalization.
    Whiting M; Tripp JC; Lin YC; Lindstrom W; Olson AJ; Elder JH; Sharpless KB; Fokin VV
    J Med Chem; 2006 Dec; 49(26):7697-710. PubMed ID: 17181152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
    Ghosh AK; Swanson LM; Cho H; Leshchenko S; Hussain KA; Kay S; Walters DE; Koh Y; Mitsuya H
    J Med Chem; 2005 May; 48(10):3576-85. PubMed ID: 15887965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Understanding HIV protease: can it be translated into effective therapy against AIDS?
    Tang J; Lin Y; Co E; Hartsuck JA; Lin X
    Scand J Clin Lab Invest Suppl; 1992; 210():127-35. PubMed ID: 1455175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protein structure-based design of potent orally bioavailable, nonpeptide inhibitors of human immunodeficiency virus protease.
    Reich SH; Melnick M; Davies JF; Appelt K; Lewis KK; Fuhry MA; Pino M; Trippe AJ; Nguyen D; Dawson H
    Proc Natl Acad Sci U S A; 1995 Apr; 92(8):3298-302. PubMed ID: 7724556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A shape- and chemistry-based docking method and its use in the design of HIV-1 protease inhibitors.
    DesJarlais RL; Dixon JS
    J Comput Aided Mol Des; 1994 Jun; 8(3):231-42. PubMed ID: 7964924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery and optimization of nonpeptide HIV-1 protease inhibitors.
    Tummino PJ; Prasad JV; Ferguson D; Nouhan C; Graham N; Domagala JM; Ellsworth E; Gajda C; Hagen SE; Lunney EA; Para KS; Tait BD; Pavlovsky A; Erickson JW; Gracheck S; McQuade TJ; Hupe DJ
    Bioorg Med Chem; 1996 Sep; 4(9):1401-10. PubMed ID: 8894098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitors of human immunodeficiency virus-1 protease.
    Tyagi SC
    Biochem Cell Biol; 1992 May; 70(5):309-15. PubMed ID: 1497858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-based drug design approaches for predicting binding affinities of HIV1 protease inhibitors.
    Reddy MR; Erion MD
    J Enzyme Inhib; 1998; 14(1):1-14. PubMed ID: 10520756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent developments in protease activity assays and sensors.
    Ong ILH; Yang KL
    Analyst; 2017 May; 142(11):1867-1881. PubMed ID: 28487913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of the three-dimensional structures of protein target molecules in structure-based drug design.
    Greer J; Erickson JW; Baldwin JJ; Varney MD
    J Med Chem; 1994 Apr; 37(8):1035-54. PubMed ID: 8164249
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.